Twist Bioscience files prospectus for mixed shelf offering

0 min read | Published on 19 Jun 2026, 02:12 AM |Updated on 19 Jun 2026, 02:12 AM

Reviewed by

Ashish TScanX News Team

Key Highlights

Twist Bioscience has filed a prospectus for a mixed shelf offering with the SEC. The filing does not disclose the specific terms or the aggregate amount of securities to be offered. This registration allows the company to issue various types of securities over time.

*this image is generated using AI for illustrative purposes only.

Twist Bioscience has filed a prospectus for a mixed shelf offering, though the specific terms of the securities to be sold remain undisclosed. The company submitted the filing to the United States Securities and Exchange Commission (SEC) to register the offering. This move provides the company with the flexibility to offer various types of securities in the future.

Filing Details

The prospectus was filed via the SEC's EDGAR system. A mixed shelf offering allows a company to register different classes of securities, such as common stock, preferred stock, debt securities, or warrants, which it can issue over time. By filing now, Twist Bioscience positions itself to raise capital quickly when market conditions are favorable without needing to file separate paperwork for each transaction.

The document does not specify the aggregate amount of securities being registered. Consequently, the financial impact of the offering cannot be determined from the current filing. Investors will need to wait for a subsequent prospectus supplement to understand the pricing, size, and specific use of proceeds for any issuance under this shelf registration.

What strategic initiatives or expansion plans might Twist Bioscience be preparing to fund with this capital?

How will current market conditions influence the timing and pricing of the securities issued under this shelf offering?

Could this move signal a shift in Twist Bioscience's capital structure, such as increasing debt or equity financing?

TD Cowen raises Twist Bioscience price target to $89

0 min read | Published on 15 Jun 2026, 10:32 PM |Updated on 15 Jun 2026, 10:32 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

TD Cowen analyst Brendan Smith maintained a Buy rating on Twist Bioscience and increased the price target from $68 to $89, indicating a positive outlook for the stock.

*this image is generated using AI for illustrative purposes only.

TD Cowen analyst Brendan Smith has maintained a Buy rating on Twist Bioscience (NASDAQ: TWST) and raised the price target to $89, signaling increased confidence in the stock's potential. The previous target was $68. This adjustment reflects a revised outlook on the company's valuation and growth prospects.

The rating and price target update provide investors with a revised benchmark for the stock's performance. Twist Bioscience operates in the synthetic biology sector, utilizing its platform to write DNA for various applications.